NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- Xi congratulates Fudan University on 120th founding anniversary
- Dragon boat event bonds foreign competitors
- Winter wheat harvested in succession across China
- China builds momentum in rare disease treatment and care
- Scientists develop insect-inspired vision system with AI capabilities
- Measuring up a tall task for science
